Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Oncology Report

• Publication date

  2009-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3892/OR_00000415PMID 19513514
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen

  2008cited by this paper
• Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer.

  2007cited by this paper
• A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.

  2007cited by this paper
• A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.

  2007cited by this paper
• Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.

  2006cited by this paper
• Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.

  2006cited by this paper
• Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.

  2005cited by this paper
• Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.

  2005cited by this paper
• Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non–Small Cell Lung Cancer Patients

  2005cited by this paper
• Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.

  2005cited by this paper
• Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) – novel predictors for response and survival in gastric cancer patients

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Glutathione S-transferase P 1 Genotype and Prognosis in Hodgkin ’ s Lymphoma

  2005cited by this paper
• ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer

  2005cited by this paper
• Association of GSTP1 Polymorphism and Survival for Esophageal Cancer

  2005cited by this paper
• Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma

  2005cited by this paper
• Risk Factors for Severe Hyperbilirubinemia in Neonates

  2004cited by this paper
• Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.

  2004cited by this paper
• A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

  2004cited by this paper
• Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil‐based chemotherapy in advanced colorectal cancer patients

  2004cited by this paper
• Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study.

  2004cited by this paper
• Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

  2004cited by this paper
• Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.

  2004cited by this paper
• XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.

  2004cited by this paper
• A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels.

  2004cited by this paper
• Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients.

  2003cited by this paper
• Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer

  2003cited by this paper
• Activity Gene Abolishes USF-1 Binding and Alters Transcriptional Thymidylate Synthase Tandem Repeat Polymorphism of the ′ A Novel Single Nucleotide Polymorphism within the 5

  2003cited by this paper
• ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.

  2003cited by this paper
• Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer.

  2002cited by this paper
• Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.

  2002cited by this paper
• Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer.

  2002cited by this paper
• UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

  2002cited by this paper
• Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia.

  2001cited by this paper
• Patient survival after D1 and D2 resections for gastric cancer: long-term results of MRC randomized surgical trial

  2001cited by this paper
• ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

  2001cited by this paper
• Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression.

  2001cited by this paper
• Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

  2001cited by this paper
• ERCC1: A comparative genomic perspective

  2001cited by this paper
• Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

  2001cited by this paper
• A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.

  2001cited by this paper
• Glutathione S-transferase-pi gene expression and platinum drug exposure in human lung cancer.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.

  2000cited by this paper
• Patient survival after D 1 and D 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial

  1999cited by this paper
• Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

  1999cited by this paper
• Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers.

  1999cited by this paper
• ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

  1998cited by this paper
• Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer.

  1997cited by this paper
• Chemotherapy of gastric cancer.

  1996cited by this paper
• A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms.

  1996cited by this paper
• Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

  1994cited by this paper
• Perspectives on stomach cancer.

  1994cited by this paper
• ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients.

  1992cited by this paper

• Association study of TYMS gene expression with TYMS and ENOSF1 genetic variants in neoadjuvant chemotherapy response of gastric cancer

  2024cites this paper
• Genetic polymorphisms and platinum-induced hematological toxicity: a systematic review

  2024cites this paper
• Predictive and prognostic value of excision repair cross-complementing group 1 in patients with advanced gastric cancer

  2024cites this paper
• Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity.

  2022cites this paper
• Utility of Pretreatment Blood Platelet-To-Lymphocyte Ratio in Prediction of Clinical Outcomes and Chemosensitivity in Patients with Advanced Gastric Cancer: A Meta-Analysis

  2021cites this paper
• The role of single strand break repair pathways in cellular responses to camptothecin induced DNA damage.

  2020cites this paper
• Glutathione S-transferases genes variants and chemotherapy efficacy in gastrointestinal cancer patients: a meta-analysis based on 50 pharmacogenetic studies

  2019cites this paper
• Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy

  2017cites this paper
• The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.

  2017cites this paper
• A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy

  2016cites this paper
• Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies

  2016cites this paper
• Can GSTM1 and GSTT1 polymorphisms predict clinical outcomes of chemotherapy in gastric and colorectal cancers? A result based on the previous reports

  2016cites this paper
• Role of GSTM1 Copy Number Variant in the Prognosis of Thai Colorectal Cancer Patients Treated with 5-FU-based Chemotherapy

  2016cites this paper
• Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis

  2016cites this paper
• Platinum-induced neurotoxicity and preventive strategies: past, present, and future.

  2015cites this paper
• Pathogenesis of neurotoxicity and role of signaling in the efficacy of anticancer agents

  2015cites this paper
• Excision repair cross-complementary group for chemotherapy efficacy in gastric cancer

  2015influential citation
• Informative gene network for chemotherapy-induced peripheral neuropathy

  2015cites this paper
• The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis

  2014cites this paper
• The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis

  2014cites this paper
• UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians

  2014cites this paper
• Polymorphism of methylenetetrahydrofolate reductase gene is associated with response to fluorouracil‐based chemotherapy in Chinese patients with gastric cancer

  2014cites this paper
• Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers.

  2014cites this paper
• Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients

  2014cites this paper
• Management of side effects in the personalized medicine era: chemotherapy-induced peripheral neuropathy.

  2014cites this paper
• Nucleotide excision repair related gene polymorphisms and genetic susceptibility, chemotherapeutic sensitivity and prognosis of gastric cancer.

  2014cites this paper
• Biotoxicity of Chemotherapy

  2014cites this paper
• Prediction of Chemotherapy Toxicities

  2013cites this paper
• Prognostic Significance of Serum Levels of Vascular Endothelial Growth Factor and Insulin-Like Growth Factor-1 in Advanced Gastric Cancer Patients Treated with FOLFOX Chemotherapy

  2013cites this paper
• Polymorphism of TS 3′-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel

  2013cites this paper
• The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer

  2013cites this paper
• Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy

  2013cites this paper
• Gastric cancer pharmacogenetics: progress or old tripe?

  2013cites this paper
• Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review

  2012influential citation
• The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma.

  2012cites this paper
• Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia

  2012cites this paper
• Tegafur–uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle

  2012cites this paper
• Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.

  2012cites this paper
• Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.

  2011cites this paper
• ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis

  2011cites this paper
• Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis

  2011cites this paper
• Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX.

  2010cites this paper
• ERCC1: impact in multimodality treatment of upper gastrointestinal cancer.

  2010cites this paper
• Pharmacogenomics and Personalized Medicine Dovepress

  year unknowncites this paper